KOSDAQ-listed QuantaMatrix shares were strong early in the session on the 22nd. Buying appears to be driven by securities analysts' views that its sepsis diagnostic equipment could enter 30 countries overseas.
As of 9:18 a.m. that day, QuantaMatrix was trading at 4,900 won, up 595 won (13.82%) from the previous session.
Independent research firm Value Finder said in a report that day, "QuantaMatrix is the first domestic bio corporations to be selected for support by the U.S. government's global antimicrobial resistance response project 'CARB-X,'" and analyzed that momentum for entry into 30 overseas countries would stand out.
QuantaMatrix, a manufacturer of rapid antibiotic susceptibility testing products, has been published in the journal Nature for the first time in the domestic diagnostics industry with the world's fastest antibiotic susceptibility test.
Sepsis is a deadly disease whose survival rate drops 7% to 9% per hour and is the No. 1 direct cause of death. Because it takes at least three days to identify a targeted antibiotic, the golden hour is often missed, and it is known that 50 million people are infected and 11 million die every year worldwide.
Lee Chung-heon, a Value Finder researcher, said, "The strength of the dRAST rapid antibiotic susceptibility testing device is that it can provide the results within 24 hours," adding, "In Korea, it has been listed for health insurance as a selective benefit, and we understand that distributor contracts have been completed in 30 countries worldwide, centered on Europe."
The researcher added, "In addition, we are developing the uRAST device, which performs blood culture and identification in one step, with the goal of launching it within three years."